XLV vs. IBBQ: Is Broad Healthcare Exposure or Biotech Growth the Better ETF Buy?

XLV, a broad healthcare ETF, offers lower costs (0.08% expense ratio) and higher dividend yield (1.60%) with more stability, while IBBQ, a concentrated biotech ETF, delivered stronger one-year returns (45.52% vs 26.79%) but with significantly higher volatility and drawdown risk. The choice depends on investor risk tolerance and investment objectives.

08/01/2026, 5:11 PM • The Motley Fool

Healthcare Stocks Are Having a Good Year. Should You Buy a Fidelity or iShares ETF to Profit?

The article compares two healthcare-focused ETFs: Fidelity MSCI Health Care Index ETF (FHLC) and iShares U.S. Healthcare ETF (IYH). FHLC is recommended as the better choice due to its significantly lower expense ratio (0.08% vs 0.38%), broader diversification with 334 holdings versus 100, and consistent outperformance across multiple time periods. Over 10 years, a $10,000 investment in FHLC would have yielded approximately $1,900 more than IYH.

08/01/2026, 1:28 PM • The Motley Fool

VHT vs. PBE: Which Health Care ETF Is the Better Buy?

The Vanguard Health Care ETF (VHT) offers broad healthcare exposure with a low 0.09% expense ratio and 423 holdings, while the Invesco Biotechnology & Genome ETF (PBE) provides focused biotech exposure with 31 holdings and higher growth potential. PBE delivered a stronger 40.88% one-year return but experienced greater volatility with a 37.84% maximum drawdown, while VHT returned 27.85% with lower risk. VHT suits conservative investors seeking steady, low-cost exposure, while PBE appeals to risk-tolerant investors chasing biotech innovation.

07/30/2026, 9:09 AM • The Motley Fool

Vanguard Health Care ETF Outperforms VanEck Biotech on Returns, Yield, and Fees

Vanguard Health Care ETF (VHT) outperforms VanEck Biotech ETF (BBH) with lower fees (0.09% vs 0.35%), higher dividend yield (1.6% vs 0.5%), and superior 5-year returns ($1,278 vs $1,004 on $1,000 invested). VHT offers broad diversification across 411 healthcare holdings, while BBH provides concentrated biotech exposure with 25 stocks and higher volatility.

07/28/2026, 8:20 AM • The Motley Fool

XLV vs FHLC: Which Healthcare ETF Fits Your Portfolio?

The State Street Health Care Select Sector SPDR ETF (XLV) and Fidelity MSCI Health Care Index ETF (FHLC) both offer low-cost healthcare exposure with identical 0.08% expense ratios. XLV focuses on 60 mega-cap healthcare stocks and has delivered stronger 5-year returns ($1,332 vs $1,276 on $1,000 invested), higher dividend yield (1.60% vs 1.30%), and greater liquidity with $41.7B in AUM. FHLC provides broader diversification with 365 holdings including mid and small-cap stocks. Over 10 years, both underperformed the S&P 500 significantly, with XLV returning 157% (9.9% CAGR) and FHLC returning 159% (10.0% CAGR) versus the S&P 500's 301% (14.9% CAGR).

07/27/2026, 8:35 AM • The Motley Fool

Is the VanEck Pharmaceutical ETF or State Street Health Care ETF the Better Buy for Your Portfolio?

The article compares two healthcare ETFs: VanEck Pharmaceutical ETF (PPH), which focuses exclusively on 25 pharmaceutical companies with higher returns but higher costs, and State Street Health Care Select Sector SPDR ETF (XLV), which offers broader diversification across 60 healthcare positions with lower fees. While XLV outperforms over 10 years, PPH delivers superior 3-year and 5-year returns. The article recommends PPH for investors seeking recent performance gains, though XLV offers better cost efficiency and diversification.

07/26/2026, 1:01 PM • The Motley Fool

Why Wall Street Can't Get Enough of This Dividend King

AbbVie, a pharmaceutical company spun off from Abbott in 2013, maintains Dividend King status with an attractive 2.7% yield well above industry averages. Despite a high earnings payout ratio of 330%, the company's cash flow-based payout ratio of 60% indicates a sustainable dividend. AbbVie's strong portfolio includes blockbuster drugs like Botox and newer immunology treatments (Skyrizi and Rinvoq) that offset patent expirations. The company's recent $11 billion acquisition of Apogee further strengthens its pipeline in inflammatory and immunological diseases.

07/25/2026, 10:15 AM • The Motley Fool

2 Top Growth Stocks to Buy Right Now Without Any Hesitation

The article recommends Eli Lilly and Intuitive Surgical as outstanding healthcare stocks to buy. Eli Lilly is positioned as a leader in the rapidly growing weight management medicine market with approved drugs like Zepbound and Foundayo, plus promising pipeline candidates like retatrutide. Intuitive Surgical, despite recent underperformance and headwinds, is viewed as a buying opportunity due to the successful launch of its da Vinci 5 surgical system and strong long-term prospects driven by innovation and high switching costs.

07/24/2026, 12:30 AM • The Motley Fool

Genmab and AbbVie Provide Clarification on Phase 3 EPCORE® DLBCL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Genmab and AbbVie announced that the Phase 3 EPCORE DLBCL-1 trial evaluating epcoritamab (a T-cell engaging bispecific antibody) failed to meet its primary endpoint of overall survival in the United States when compared to standard chemotherapy in patients with relapsed/refractory diffuse large B-cell lymphoma. Despite the trial failure, epcoritamab remains approved under accelerated approval and the companies continue to evaluate the therapy in other clinical programs.

07/23/2026, 4:00 PM • GlobeNewswire

iShares Global Healthcare ETF vs VanEck Biotech ETF: Which ETF Is Better for Profiting With Healthcare in 2026?

The article compares two healthcare-focused ETFs: iShares Global Healthcare ETF (IXJ) with 110 holdings offering global diversification and lower volatility, versus VanEck Biotech ETF (BBH) with 25 concentrated biotech positions delivering higher short-term returns but greater drawdown risk. IXJ is recommended for its superior long-term performance, geographic diversity, and stability despite BBH's impressive 30.8% one-year return.

07/23/2026, 3:30 PM • The Motley Fool

I'd Double a Position in These 3 Dividend Stocks Right Now Without Any Hesitation

The article recommends three blue-chip dividend stocks as defensive investments during market uncertainty: AbbVie, benefiting from immunology therapy success and expected 10% revenue growth in 2026; Chevron, with nearly 40 years of consecutive dividend growth and potential 10% annualized earnings growth through 2030; and PepsiCo, trading at a discount with a 4.4% dividend yield and 54-year dividend increase streak despite recent market bearishness.

07/23/2026, 11:15 AM • The Motley Fool

Which Is the Better Healthcare ETF: First Trust's High-Conviction FBT or Vanguard's Low-Cost VHT?

First Trust NYSE Arca Biotechnology Index Fund (FBT) offers concentrated exposure to 30 biotech stocks with 51.6% 1-year returns but higher volatility and a 0.55% expense ratio. Vanguard Health Care ETF (VHT) provides broader diversification across 400+ healthcare companies with lower costs (0.09% expense ratio) and dividend yield, making it better for long-term stability. FBT suits investors with high risk tolerance and biotech conviction, while VHT is recommended for those seeking healthcare as a portfolio stabilizer.

07/23/2026, 8:15 AM • The Motley Fool

Which ETF Is Healthier for Your Portfolio: Vanguard Health Care ETF or iShares Pharmaceuticals ETF?

The article compares two healthcare-focused ETFs: Vanguard Health Care ETF (VHT) and iShares U.S. Pharmaceuticals ETF (IHE). VHT offers broader diversification with 411 holdings and a lower 0.09% expense ratio, while IHE provides concentrated pharmaceutical exposure with 56 holdings and has delivered superior 5-year returns (11.8% vs 5.4%). The author recommends IHE as the better buy for 2026 due to stronger recent performance and lower maximum drawdown, despite VHT's cost advantages.

07/22/2026, 4:33 PM • The Motley Fool

As Healthcare Rallies Is the Vanguard Health Care ETF of the Invesco Pharmaceuticals ETF the Better Fund for 2026?

The article compares two healthcare-focused ETFs: Vanguard Health Care ETF (VHT) and Invesco Pharmaceuticals ETF (PJP). VHT offers broader sector exposure with 411 holdings, a lower expense ratio of 0.09%, and higher dividend yield of 1.60%. PJP focuses narrowly on 29 pharmaceutical stocks with a 0.57% expense ratio and 0.90% yield. Despite VHT's cost advantages, PJP has significantly outperformed over 3 and 5-year periods (17.3% and 9.1% returns respectively), leading the author to recommend PJP as the better buy for 2026.

07/22/2026, 3:13 PM • The Motley Fool

3 Reasons to Buy AbbVie Stock Like There's No Tomorrow

AbbVie has demonstrated strong recovery after Humira's patent loss, with immunology drugs Skyrizi and Rinvoq exceeding sales expectations and not facing biosimilar competition until 2033. The company maintains a promising pipeline including weight-loss therapy ABBV-295 and acquired eczema treatment zumilokibart. AbbVie's Dividend King status with 203.5% dividend increases over the past decade and a 2.7% yield makes it an attractive long-term investment despite near-term headwinds from Humira decline and Imbruvica pricing pressure.

07/21/2026, 6:30 PM • The Motley Fool